Taw qhia
Tirzepatide, tsim los ntawm Eli Lilly, yog cov tshuaj peptide tshiab uas sawv cev rau qhov tseem ceeb hauv kev kho mob ntshav qab zib hom 2 thiab rog rog. Tsis zoo li ib txwm siv GLP-1 (glucagon-zoo li peptide-1) agonists, Tirzepatide ua rauob qho tib si GIP (glucose-dependent insulinotropic polypeptide)thiabGLP-1 receptors, khwv tau nws lub npe ntawm adual receptor agonist. Qhov kev siv ob npaug no ua rau muaj txiaj ntsig zoo hauv kev tswj cov ntshav qabzib thiab txo lub cev hnyav, tshwj xeeb tshaj yog rau cov neeg mob ntshav qab zib hom 2 thiab rog rog.
Mechanism ntawm Action
-
GIP receptor activation: Txhim kho cov tshuaj insulin secretion thiab txhim kho cov piam thaj hauv siab.
-
GLP-1 receptor activation: Txhawb kev tso tawm insulin, inhibits glucagon secretion, thiab slows plab hnyuv.
-
Dual kev sib koom ua ke: Muab kev tswj glycemic zoo thiab txo qhov hnyav.
Clinical Data Analysis
1. SURPASS Trials (Tim 2 Ntshav Qab Zib)
Nyob ntawm ntau yamSURPASS kev sim tshuaj, Tirzepatide outperformed insulin thiab Semaglutide hauv glycemic thiab qhov hnyav txo qhov tshwm sim.
| Pab neeg mob | Koob tshuaj | Avg. Kev txo qis HbA1c | Avg. Poob poob |
|---|---|---|---|
| Hom 2 Ntshav Qab Zib | 5mg ib | -2.0% | - 7.0 kg |
| Hom 2 Ntshav Qab Zib | 10 mg | -2.2% | - 9.5 kg |
| Hom 2 Ntshav Qab Zib | 15 mg ib | -2.4% | - 11.0 kg |
➡ Muab piv rau Semaglutide (1 mg: HbA1c -1.9%, Nyhav -6.0 kg), Tirzepatide pom tau zoo tshaj plaws hauv kev tswj glycemic thiab poob phaus.
2. SURMONT Kev sim (Obesity)
Hauv cov neeg mob rog rog yam tsis muaj ntshav qab zib, Tirzepatide tau pom tias muaj txiaj ntsig zoo heev.
| Koob tshuaj | Avg. Txo qhov hnyav (72 lub lis piam) |
|---|---|
| 5mg ib | -15% |
| 10 mg | -20% |
| 15 mg ib | -22.5% |
➡ Rau tus neeg mob hnyav 100 kg, koob tshuaj Tirzepatide tuaj yeem ua tiav qhov hnyav ntawm ib puag ncig22.5 kg ib.
Qhov Zoo Tshaj Plaws
-
Dual mechanism: Tshaj ib leeg GLP-1 agonists.
-
Superior kev ua tau zoo: Siv tau zoo hauv kev tswj glycemic thiab tswj qhov hnyav.
-
Kev siv dav dav: Haum rau ob qho tib si ntshav qab zib thiab rog rog.
-
Muaj peev xwm ua lag luam siab: Kev thov nce rau kev kho mob rog txoj haujlwm Tirzepatide ua cov tshuaj tiv thaiv yav tom ntej.
Market Outlook
-
Kev lag luam loj kwv yees: Txog xyoo 2030, lub khw muag tshuaj GLP-1 thoob ntiaj teb tau kwv yees ntau duaUSD 150 billion, nrog Tirzepatide zoo li yuav ntes tau ib feem tseem ceeb.
-
Kev sib tw toj roob hauv pes: Cov neeg sib tw tseem ceeb yog Novo Nordisk's Semaglutide (Ozempic, Wegovy).
-
Qhov zoo: Cov ntaub ntawv kho mob qhia Tirzepatide muab kev poob phaus zoo dua piv rau Semaglutide, ntxiv dag zog rau nws txoj kev lag luam kev sib tw hauv kev kho mob rog.
Post lub sij hawm: Sep-12-2025